The main purpose of this study was to investigate whether the length of sentences has influence on the frequency of speech disfluencies for children who stutter. The participants included 30 children who stutter 19 male participants and 13 female participants, whose age ranged between 4 years and 8 months to 6 years and 11 months (56 to 83 months of age). Research was conducted in kindergartens and primary schools in Tuzla Canton in Bosnia and Herzegovina2 . The test consisted of 36 sentences. In relation to the length, sentences were divided into three groups: in the first group there were 9 sentences which included 3 to 5 words, in the second group, there were 14 sentences which included 6 to 8 words and in the third group there were 13 sentences which included 9 to 11 words. Testing was conducted so that the examiner was pronouncing one sentence after which the participant repeated the same sentence. Each participant was requested to repeat exactly what he/she had heard. Speech and language pathologist has recorded all speech disfluencies in all sentences. The results showed that the sentences containing 9 to 11 words had most effects on the overall dynamics of speech disfluencies in children who stutter. The results suggest that during the process of assessment and diagnosis of children who stutter, it should be required to assess the child's ability to use complex linguistic statements and to assess the frequency of disfluencies in relation to the complexity of the sentences. Precision diagnostics would provide guidelines for the treatment of stuttering in terms of implementation of approaches and strategies which include language treatment and gradually increasing the length and complexity of statements of children who stutter during speech.

Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency disease (PID) among adults. CVID consists of two phenotypes – one in which infections are the characteristic and another in which impressive inflammatory and/or hematological complications also develop, including lymphadenopathy, splenomegaly, autoimmune cytopenias, enteropathy, and granulomatous disease. These phenotypes appear to be stable, are related to immunological and inflammatory markers, and are predictive of outcomes. Both subcutaneous immunoglobulin (SCIG) and intravenous immunoglobulin (IVIG) are equally effective for replacement therapy. No data are available about specific factors affecting the quality of life related to switching from IVIG to SCIG in the Arabian Gulf area. We present the case reports of three adult CVID patients, who were shifted from IVIG to SCIG by the US conversion method (1 : 1.5). We followed-up patients for clinical outcomes, side-effects, immunoglobulin G (IgG) trough levels, annual infection rate, and quality of life using questionnaires (RAND-36) over a 3-year period. Three patients (two females and one male), with a mean age of 26 years, had received IVIG [Gamunex-C (Grifols Therapeutics Inc., NC, 27709 USA) 10%; Grifols] treatment for an average duration of 4 years and had average IgG trough levels of 7.7±2.9 g/dl. Patients were shifted to SCIG [Subcuvia (Baxalta Innovation GmbH, Vienna, Austria) 10%; Baxter] for different reasons. SCIG was administered, using an infusion pump, under medical supervision at the hospital, on a weekly basis. The average IgG trough level on SCIG was 10.4±1.5 g/dl. The annual infection rate of pneumonias, sinusitis, otitis media, and others significantly declined after switching to SCIG in all three patients. However, while on IVIG treatment, some patients reported headache and malaise, but when on the SCIG treatment the reactions were mild and infusion site-related such as erythema, swelling, and itching. Remarkably, all patients were successfully switched to SCIG with significant decrease in the annual rate of infections and a favorable steady-state of serum trough levels of IgG. The use of SCIG was generally associated with notable improvement in physical, emotional, and social health.